中国中医药信息杂志2025，Vol.32Issue(6)：160-166,7.DOI:10.19879/j.cnki.1005-5304.202411423
含砷中药复方治疗高危骨髓增生异常综合征脾肾两虚、毒瘀阻滞证临床研究
Clinical Study on Arsenic-containing TCM Compounds for the Treatment of High-risk Myelodysplastic Syndrome with Spleen-kidney Deficiency and Toxic Stagnation and Blood Stasis Syndrome
摘要
Abstract
Objective To analyze the efficacy of arsenic-containing TCM compounds in treating high-risk myelodysplastic syndromes(HR-MDS)with spleen-kidney deficiency and toxic stagnation and blood stasis syndrome;To provide references for the clinical treatment of HR-MDS.Methods The medical records of HR-MDS with spleen-kidney deficiency and toxic stagnation and blood stasis syndrome treated with arsenic-containing TCM compounds in Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2016 to September 2022 were retrospectively analyzed.The patients were divided into arsenic-containing TCM compounds combined with demethylation drugs(HMAs)treatment group and arsenic-containing TCM compounds combined with androgen treatment group.The clinical efficacy of both groups were evaluated,including overall response rate(ORR),median overall survival(OS),1-,2-and 3-year survial rates,median progression free survival(PFS),and 1-,2-and 3-year PFS rates.Results Among 200 cases of HR-MDS,68 cases were treated with arsenic-containing TCM compounds combined with HMAs,and 132 cases were treated with arsenic-containing TCM compounds combined with androgen.The ORR was 30%,and the OS of HR-MDS after treatment was 42 months.The 1-,2-and 3-year survival rates were 78.6%,60.4%and 50.2%respectively.The median PFS was 15 months,and the 1-year,2-year and 3-year PFS rates were 57.8%,28.8%and 18.2%respectively.The ORR of 68 cases HR-MDS treated with arsenic-containing TCM compounds combined with HMAs was 44.1%.After treatment,the median OS of HR-MDS was 42 months,and the survival rates of 1-,2-and 3-years were 84%,75.6%and 61.9%respectively,and the median PFS was 24 months,and the PFS rates of 1-,2-and 3-years were 74.3%,48.5%and 35.2%,respectively.The ORR of 132 cases of HR-MDS treatmented with arsenic-containing TCM compounds combined with androgen was 26.5%,including 33.3%in the high-risk group of HR-MDS and 13.3%in the extremely high-risk group of HR-MDS.There was statistical significance between the two groups(P=0.014).After treatment,the median OS of HR-MDS was 29 months,and the survival rates of 1-,2-and 3 years were 78.6%,54.1%and 45.1%respectively.The median PFS was 13 months,and the PFS rates of 1-,2-and 3 years were 54.1%,28.2%and 12.9%respectively.Conclusion The arsenic-containing TCM compounds combined with HMAs can significantly prolong survival and delay disease progression in HR-MDS.Although the arsenic-based TCM compounds combined with androgen therapy demonstrate inferior efficacy compared to HMAs-based regimens,it has achieved significantly higher OS and PFS than historical controls,serving as an effective alternative for patients intolerant to HMAs.关键词
含砷中药复方/高危骨髓增生异常综合征/回顾性研究/临床疗效/血液病Key words
arsenic-containing TCM compounds/high-risk myelodysplastic syndrome/retrospective study/clinical efficacy/hemopathy分类
医药卫生引用本文复制引用
靳楠,毛悦,吕妍,陈卓,王德秀,刘为易,刘驰,唐旭东..含砷中药复方治疗高危骨髓增生异常综合征脾肾两虚、毒瘀阻滞证临床研究[J].中国中医药信息杂志,2025,32(6):160-166,7.基金项目
国家自然科学基金面上项目(82074258、82274502) （82074258、82274502）
第二批北京市研究型病房示范建设项目(BCRW202108) （BCRW202108）
中国中医科学院科技创新工程重大攻关项目(CI2021A01701) （CI2021A01701）
